Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert C. Flaumenhaft, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Robert Flaumenhaft and Bruce Furie.
Connection Strength

3.391
  1. Vascular thiol isomerases. Blood. 2016 08 18; 128(7):893-901.
    View in: PubMed
    Score: 0.687
  2. Thiol isomerases in thrombus formation. Circ Res. 2014 Mar 28; 114(7):1162-73.
    View in: PubMed
    Score: 0.588
  3. A coagulation defect arising from heterozygous premature termination of tissue factor. J Clin Invest. 2020 10 01; 130(10):5302-5312.
    View in: PubMed
    Score: 0.231
  4. Thiol isomerase ERp57 targets and modulates the lectin pathway of complement activation. J Biol Chem. 2019 03 29; 294(13):4878-4888.
    View in: PubMed
    Score: 0.205
  5. Protein disulfide isomerase regulation by nitric oxide maintains vascular quiescence and controls thrombus formation. J Thromb Haemost. 2018 11; 16(11):2322-2335.
    View in: PubMed
    Score: 0.201
  6. Kinetic-based trapping by intervening sequence variants of the active sites of protein-disulfide isomerase identifies platelet protein substrates. J Biol Chem. 2017 06 02; 292(22):9063-9074.
    View in: PubMed
    Score: 0.181
  7. A substrate-driven allosteric switch that enhances PDI catalytic activity. Nat Commun. 2016 08 30; 7:12579.
    View in: PubMed
    Score: 0.174
  8. Extracellular Thiol Isomerases and Their Role in Thrombus Formation. Antioxid Redox Signal. 2016 Jan 01; 24(1):1-15.
    View in: PubMed
    Score: 0.165
  9. Quercetin-3-rutinoside Inhibits Protein Disulfide Isomerase by Binding to Its b'x Domain. J Biol Chem. 2015 Sep 25; 290(39):23543-52.
    View in: PubMed
    Score: 0.161
  10. Defective PDI release from platelets and endothelial cells impairs thrombus formation in Hermansky-Pudlak syndrome. Blood. 2015 Mar 05; 125(10):1633-42.
    View in: PubMed
    Score: 0.155
  11. Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease. Arterioscler Thromb Vasc Biol. 2015 Jan; 35(1):16-23.
    View in: PubMed
    Score: 0.151
  12. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest. 2012 Jun; 122(6):2104-13.
    View in: PubMed
    Score: 0.129
  13. Interactions of platelets, blood-borne tissue factor, and fibrin during arteriolar thrombus formation in vivo. Microcirculation. 2005 Apr-May; 12(3):301-11.
    View in: PubMed
    Score: 0.079
  14. In vivo models of platelet function and thrombosis: study of real-time thrombus formation. Methods Mol Biol. 2004; 272:187-97.
    View in: PubMed
    Score: 0.072
  15. Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels. Blood. 2004 Mar 15; 103(6):2127-34.
    View in: PubMed
    Score: 0.072
  16. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019 02 21; 4(4).
    View in: PubMed
    Score: 0.052
  17. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight. 2017 01 12; 2(1):e89373.
    View in: PubMed
    Score: 0.045
  18. A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase. J Cell Mol Med. 2016 10; 20(10):1851-60.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.